Alpha-MSH darkens skin and also calms inflammatory signalling. KPV is the three-amino-acid end of it, studied to see whether the second job survives on its own.
KPV · Alpha-MSH tripeptide fragment
Some hormones do more than one thing. Alpha-melanocyte-stimulating hormone is best known for pigmentation, but it also dampens inflammatory signalling in immune cells. Researchers ask whether those two activities live in different parts of the molecule. KPV, a fragment from one end, is the test case. The evidence so far is from cells and rodent models of bowel inflammation, not people.
KPV is a tripeptide, three amino acids long: lysine, proline and valine. It corresponds to the last three residues of alpha-melanocyte-stimulating hormone (alpha-MSH), a 13-amino-acid hormone made from the same precursor as adrenocorticotropic hormone. Alpha-MSH acts on melanocortin receptors, cellular receivers found on pigment cells, in the brain and on immune cells.
The fragment idea dates from 1989, when the end sequence of alpha-MSH was reported to retain anti-inflammatory activity in animals while lacking the hormone’s pigmentary effect (Hiltz and Lipton, 1989). How KPV acts is not settled: proposed routes include entry into cells through the peptide transporter PepT1 and interference with NF-kappaB, a switch that turns on inflammatory genes, rather than classical melanocortin receptor activation. KPV is one of several tripeptides in the Pulse catalogue; its size is a feature of the research question, not a distinction.
The main setting is experimental colitis, inflammation of the large bowel induced in mice. Dalmasso and colleagues showed in cultured intestinal epithelial and immune cells that KPV is taken up through PepT1 and reduced inflammatory signalling, then gave KPV orally in drinking water to mice with chemically induced colitis and measured body weight, tissue damage and inflammatory markers (Dalmasso et al., 2008). In the same year a German group reported reduced inflammation with KPV in two mouse models of inflammatory bowel disease (Kannengiesser et al., 2008).
Later work has focused on delivery. Xiao and colleagues packaged KPV in hyaluronic acid-coated nanoparticles designed to reach inflamed colon tissue after oral dosing in mice, reporting effects at far lower peptide amounts than free KPV (Xiao et al., 2017). A 2008 review in Endocrine Reviews places KPV within the broader alpha-MSH literature, including cell studies of immune cells and other animal inflammation models (Brzoska et al., 2008). All of these anti-inflammatory observations are preclinical: cells and rodents. No clinical trial of KPV in people was identified.
Whether KPV has any effect in people is untested; a mouse colitis model is a deliberately simplified version of human bowel disease. Route matters: the strongest animal data use oral delivery to the gut lining, and say nothing about injected material or tissues outside the intestine. The mechanism is also open, with transporter uptake, intracellular signalling and receptor effects all proposed and none confirmed as the operative one in vivo. The literature is small, and effect sizes vary with the model and formulation used.
KPV is not an approved medicine in Australia and is not listed in the Poisons Standard (June 2026). No overseas regulator has approved KPV as a medicine.
Sources and status checked 2026-09-22
KPV — sizes and pricing